Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More